Researchers are creating real-time epidemiology registry to evaluate the efficacy of COVID-19 subject risk assessment scores based on recording of symptoms, biomarkers, chronic illness and mental health assessments with digital technology using wearables and mobile app tools. Researchers aim to study in Phase 1, epidemiological variations in COVID-19 presentation in both PCR positive and negative subjects in the registry. Assessment of variables, predictive modeling of variables that impact severity of COVID-19 positive and negative subjects and assessment of predictors for post COVID-19 complications. In Phase 2, 2700 subjects with COVID-19 positive test will be studied in the intervention group comparing ECL-19 vs placebo with primary end point of hospital admission assessment. Treatment strategy for PCR positive COVID-19 subjects in the registry who are in Stage I of the disease process with ECL-19 drug compared to placebo in reducing hospital admissions
Investigators aim is to create a real time COVID-19 Coromec epidemiology registry to assess
the feasibility of monitoring subject infection progress using Vitalbeat digital therapeutics
monitoring platform for remote patient monitoring and integrated chronic disease management
with mobile app, AI-bot, IoT wearables and cloud computing algorithms developed by health
technology company Aventyn, Inc., in collaboration with Intel Corp., clinicians and
scientists from Baylor Heart, Abrazo Health, Karolinska Institute, Dignity Health. Coromec
registry is a real time epidemiology solution deploying Vitalbeat for pandemic public health
stakeholders to enable immediate reporting, assess subject risk prediction for COVID-19
avoiding hospitalization.
The digital health technology aims to assess predictors of risk and predictors of preventing
COVID-19, assess what preventive strategies are being used and the efficacy of treatment
strategies for avoiding hospitalization. The platform launched globally and is available on
the public internet at www.coromec.org
Users can self-report symptoms, mental health assessment, chronic illness status and vital
sign measures on a daily basis for risk assessment and preventive treatment with a variety of
digital tools by downloading Coromec mobile app, access interactive chatbots and the Coromec
real time epidemiology website Researchers aim to study ECL-19 as a drug treatment in
stabilizing the endothelium as the first line of approach in COVID 19 positive subjects that
may quickly restore their glycocalyx and endothelium thus avoiding hospitalizations and
progression of disease with ECL-19
A validated approach would enable vulnerable subjects and communities access to pandemic
care. Registry data can assist public health scientists in further studies and enable global
registries in future pandemic emergencies to help better understand use of digital tools,
intelligent algorithms and predict risk outcomes with targeted novel treatment strategies
Drug: Coromec Registry with ECL-19
Glycocheck to assess Microvascular Score will be used on all patients. An algorithm-based identification of symptoms and objective evidence using care coordination and remote sensor driven technology
Other Name: Glycocheck
Inclusion Criteria:
- COVID-19 PCR positive
- COVID-19 PCR negative
- COVID-19 PCR pending
- COVID-19 high risk score
Exclusion Criteria:
- Subjects unwilling to participate in the study before, during or after consent
- Patients considered unreliable by the investigator concerning the requirements for
follow-up visits.
Multiple Locations
Phoenix, Arizona, United States
Multiple Locations
Bangalore, India
Multiple Locations
Stockholm, Sweden
Kris Vijay, MD
2317942328
coromec@aventyn.com
Navin Govind
2317942328
coromec@aventyn.com